GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

Xvivo Perfusion XVIVO.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

200.80

+1.67%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SEK, from our data supplier.

FY2025

Revenue

SEK 812.2m

FY2016FY2025

Net income

SEK 25.2m

FY2016FY2025

Free cash flow

—

FY2016FY2025

Shareholders' equity

SEK 2.11bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueSEK 812.2mSEK 822.4mSEK 597.5mSEK 415.3mSEK 258.4mSEK 179.9mSEK 220.8mSEK 187.9mSEK 148.3mSEK 138.2m
Gross profitSEK 533.5mSEK 616.4mSEK 445.1mSEK 297.0mSEK 188.3mSEK 133.0mSEK 162.8mSEK 136.0mSEK 113.4mSEK 102.2m
Research and developmentSEK 100.7mSEK 148.3mSEK 135.9mSEK 69.3mSEK 54.0mSEK 56.2mSEK 62.7mSEK 47.9mSEK 39.5mSEK 36.7m
Operating incomeSEK 93.0mSEK 88.4mSEK 10.0mSEK 23.2mSEK 7.0m−SEK 56.7mSEK 5.6mSEK 14.0mSEK 7.2mSEK 3.0m
Net incomeSEK 25.2mSEK 172.2mSEK 91.8mSEK 18.4mSEK 8.2m−SEK 43.7mSEK 4.9mSEK 12.7mSEK 6.3mSEK 1.5m
Diluted earnings per share0.805.442.910.620.28-1.530.190.480.240.06

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsSEK 2.37bnSEK 2.40bnSEK 2.20bnSEK 1.73bnSEK 1.54bnSEK 1.15bnSEK 634.5mSEK 586.6mSEK 538.5mSEK 349.3m
Cash and short-term investmentsSEK 292.1mSEK 415.5mSEK 546.1mSEK 246.5mSEK 398.7mSEK 353.4mSEK 159.1mSEK 186.3mSEK 195.0mSEK 23.4m
Total liabilitiesSEK 260.7mSEK 246.0mSEK 250.6mSEK 302.9mSEK 257.1mSEK 141.8mSEK 57.0mSEK 46.1mSEK 34.2mSEK 32.9m
DebtSEK 124.7mSEK 34.0mSEK 31.4mSEK 10.0mSEK 5.7mSEK 7.2mSEK 5.5m———
Shareholders' equitySEK 2.11bnSEK 2.16bnSEK 1.95bnSEK 1.43bnSEK 1.29bnSEK 1.01bnSEK 577.5mSEK 540.5mSEK 504.3mSEK 316.4m
Shares outstanding32m32m31m30m29m29m27m26m26m24m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsSEK 101.1mSEK 111.3mSEK 46.3mSEK 27.9m−SEK 12.1m−SEK 12.3mSEK 29.5mSEK 23.6mSEK 22.2mSEK 12.6m
Capital spending−SEK 101.1m−SEK 193.2m−SEK 43.0m−SEK 130.9m−SEK 94.1m−SEK 64.7m−SEK 83.7m−SEK 54.7m−SEK 34.9m−SEK 20.5m
Free cash flow—−SEK 81.9mSEK 3.3m−SEK 103.1m−SEK 106.1m−SEK 76.9m−SEK 54.2m−SEK 31.1m−SEK 12.7m−SEK 8.0m
Dividends paid———−SEK 7.3m——————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueSEK 239.0mSEK 241.0mSEK 226.1mSEK 189.1mSEK 178.3mSEK 218.6mSEK 227.6mSEK 198.5m
Gross profitSEK 151.1mSEK 171.0mSEK 114.6mSEK 125.9mSEK 132.7mSEK 160.4mSEK 175.1mSEK 147.9m
Operating incomeSEK 22.0mSEK 31.9mSEK 41.0mSEK 18.3mSEK 7.1mSEK 26.6mSEK 15.5mSEK 20.5m
Net incomeSEK 16.3mSEK 36.3mSEK 31.6mSEK 4.3mSEK 1.6m−SEK 12.4mSEK 36.4mSEK 85.8m
Diluted earnings per share0.521.151.000.140.05-0.391.152.71
Cash from operationsSEK 63.0mSEK 65.0mSEK 86.0mSEK 20.0mSEK 8.0m−SEK 15.0mSEK 62.0mSEK 22.0m
Capital spending−SEK 63.0m−SEK 10.0m−SEK 86.0m−SEK 20.0m−SEK 8.0m−SEK 15.0m−SEK 62.0m−SEK 10.0m
Free cash flowSEK 0SEK 55.0mSEK 0SEK 0SEK 0−SEK 30.0mSEK 0SEK 12.0m
Total assetsSEK 2.53bnSEK 2.47bnSEK 2.37bnSEK 2.38bnSEK 2.39bnSEK 2.30bnSEK 2.40bnSEK 2.28bn
Cash and short-term investmentsSEK 305.0mSEK 308.1mSEK 292.1mSEK 279.9mSEK 323.0mSEK 315.9mSEK 415.5mSEK 450.0m
DebtSEK 11.7mSEK 11.4mSEK 124.7mSEK 124.5mSEK 110.8mSEK 29.3mSEK 45.0mSEK 9.8m
Shareholders' equitySEK 2.20bnSEK 2.17bnSEK 2.11bnSEK 2.09bnSEK 2.09bnSEK 2.09bnSEK 2.16bnSEK 2.08bn

Financial ratios

Data as of 14 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin65.7%75.0%74.5%71.5%72.9%73.9%
Operating margin10.2%25.0%0.7%5.6%2.7%-31.5%
Net margin3.1%20.9%15.4%4.4%3.2%-24.3%
Return on equity1.2%8.0%4.7%1.3%0.6%-4.3%
Return on assets1.1%7.2%4.2%1.1%0.5%-3.8%
Free cash flow yield2.9%4.3%1.3%2.4%1.3%0.8%
Revenue growth-1.2%37.6%43.9%60.7%43.7%-18.6%
Earnings growth-85.4%87.5%398.3%126.0%-118.6%-985.5%
Current ratio5.77x4.58x6.14x3.47x5.24x6.41x
Debt to equity0.04x0.01x0.01x0.01x0.01x-0.04x
Equity ratio89.0%89.8%88.6%82.5%83.3%87.7%
Interest coverage1.87x36.70x3.52x21.40x25.15x-100.89x
R&D as a share of sales12.4%18.0%22.8%16.7%20.9%31.2%
Buybacks as a share of market value0.3%-0.5%-6.4%-0.7%-2.8%-7.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue25.1%35.2%21.0%
Operating income58.9%—29.1%
Net income10.9%—17.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin70.3%71.5%71.7%72.1%
Operating margin11.1%8.1%5.3%5.2%
Net margin12.1%11.6%8.8%7.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings234.089.9113.0294.0—-205.3—274.7393.3—
Price to sales7.318.817.413.031.749.920.518.616.615.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.